Track ARCT and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Arcturus Therapeutics Holdings Inc
10285 Science Center Drive, San Diego, CA, United States, 92121
IPO
2020
Employees
106
Industry
Biotechnology
Sector
Healthcare
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20241-1
0
Q2 20242-2
0
Q1 20242-2
0
Q4 20232-2
0
Q3 20234-4
0
Q2 20232-2
0
6-quarter cumulative
13 sells0 buys
Analyst Ratings
3 analysts covering
Buy100%recommend buy
Buy
3
Hold
0
Sell
0